The change was made to the source (manufacturer) of polyethylene glycol 4000: after the completion of clinical trial and in the process of preparing to apply for NDA, in October 2018, it was decided to change its source from Hunan Erkang Pharmaceutical Co., Ltd. to Nanjing Weill Pharmaceutical Co., Ltd. according to the registration of polyethylene glycol 4000, the related review and risk assessment, and the corresponding research was carried out to support the change More.
正在翻译中..